12.10.14
Rick Anderson, managing director of PTV Healthcare Capital, and Mark Fletcher, president of surgical technologies of Medtronic Inc., have resigned form the board of directors for Menlo Park, Calif.-based Intersect ENT Inc., which makes the drug-eluting sinus implants Propel and Propel mini.
Anderson has served on the company’s board since 2008 and Fletcher since 2010. According to Intersect ENT, their departures are consistent with the company’s transition as a newly public company. The board recently initiated a director search to continue to build the expertise and breadth of experience represented on the company’s board.
“We have benefited greatly from our relationships with both PTV Healthcare Capital and Medtronic as investors the last several years,” said Lisa Earnhardt, president and CEO of Intersect ENT. “Rick and Mark have shared tremendous experience, insight, and encouragement as directors, and have helped us transform from an early clinical-stage start-up to a commercial stage public company. We remain grateful for their many contributions.”
“We take great pride in Intersect ENT’s accomplishments and the meaningful impact we’ve had on sinus sufferers, ENT physicians, and the healthcare system,” said Anderson. “PTV Healthcare Capital is pleased to have partnered with the board and with the Intersect ENT team. Our firm remains dedicated to enabling entrepreneurs to bring innovative technologies from product development to successful commercialization.”
Fletcher added, “Lisa and the team are well positioned to accomplish great things in the future. I’m honored to have been involved with Intersect ENT the last four years.”
Anderson has served on the company’s board since 2008 and Fletcher since 2010. According to Intersect ENT, their departures are consistent with the company’s transition as a newly public company. The board recently initiated a director search to continue to build the expertise and breadth of experience represented on the company’s board.
“We have benefited greatly from our relationships with both PTV Healthcare Capital and Medtronic as investors the last several years,” said Lisa Earnhardt, president and CEO of Intersect ENT. “Rick and Mark have shared tremendous experience, insight, and encouragement as directors, and have helped us transform from an early clinical-stage start-up to a commercial stage public company. We remain grateful for their many contributions.”
“We take great pride in Intersect ENT’s accomplishments and the meaningful impact we’ve had on sinus sufferers, ENT physicians, and the healthcare system,” said Anderson. “PTV Healthcare Capital is pleased to have partnered with the board and with the Intersect ENT team. Our firm remains dedicated to enabling entrepreneurs to bring innovative technologies from product development to successful commercialization.”
Fletcher added, “Lisa and the team are well positioned to accomplish great things in the future. I’m honored to have been involved with Intersect ENT the last four years.”